Actovegin 200 mg 50 tablets
Plaquenil 200 mg 60 tablets
Prednisolone 5mg 100 tablets
Sildenafil 100 mg 20 tablets
Tamiflu 75 mg 10 capsules
Ingavirin 90 mg 10 capsues
Ovestin 2 mg 30 tablets
Ovestin Vaginal cream 15g
Macmiror 200 mg 20 tablets
Ventolin nebula 20 ampoules
Avodart 0,5 mg 90 capsules
- Antibacterial medication
- Antifungal medication
- Antiviral Medication
- Cardiovascular medication
- different medication
- Hormonal medication
- Immunosuppressants and immunomodulating medications
- Nervous system
- Pain relievers and anti-inflammatory
- Respiratory system
- Treatment of diseases of the liver and gastrointestinal tract
- Treatment of sensory organs, eyesight and hearing
- Urogenital system
De-Nol 120mg 112 tablets
De-Nol 120mg 56 tablets
De-Nol 120mg 32 tablets
finasteride 5mg 30 tablets
Itrazole 100 mg 42 capsules
furasol 15 sachets of 100 mg
Triacort OINTMENT 0.1% 10G
Urseptia 200 mg 20 capsules
Minolexin 100 mg 20 capsules
Minolexin 50 mg 20 capsules
Immard 200 mg 30 tablets
Adenuric 120 mg 28 tablets
Champix 1 mg 112 tablets
Memoplant 80 mg 30 tablets
Cerebrolysin 10 ml 5 vials
Piracetam 800 mg 30 tablets
betaserc 24 mg 20 tablets
Cerebrolysin 2 ml 10 vials
Lamolep 25 mg 30 tablets
Vestibo 24 mg 30 tablets
Cerebrolysin 5 ml 5 vials
Cinnarizine 25 mg 50 tablets
Actovegin 10 ml 5 vials
Persen 60 tablets
Reminyl 8 mg 7 capsules
Baclosan 10 mg 50 tablets
Trileptal 150 mg 50 tablets
Сonvalis 300 mg 50 capsules
neyrobion 3 ml 3 vials
Lamolep 50 mg 30 tablets
Vinpotropil 30 capsules
Piracetam 400 mg 60 tablets
Betahistine 16 mg 30 tablets
Semax nasal drops 0.1% 3 ml
Lotosonik 10 tablets
Cavinton 5 mg 50 tablets
EGITROMB 75 mg 28 tablets
Manufacturer: * EGIS *
Country of origin: Hungary
General description: The antiplatelet agent
Pharmacological action
Antiaggregant drug. Specific and active inhibitor of platelet aggregation. Selectively reduces the binding of adenosine diphosphate (ADP) to platelet receptors and the activation of GPI Ib / IIIa receptors under the action of ADP, thereby weakening platelet aggregation.
Reduces platelet aggregation, caused by other agonists, preventing their activation by released ADP, does not affect the activity of phosphodiesterase (PDE).
Irreversibly binds to ADP-receptor platelets, which remain immune to stimulation of ADP throughout the life cycle (about 7 days). The inhibition of platelet aggregation is observed after 2 hours after administration (40% inhibition) of the initial dose. The maximum effect (60% suppression of aggregation) develops after 4-7 days of constant admission in a dose of 50-100 mg / day. Antiaggregant effect persists throughout the life span of platelets (7-10 days).
In the presence of an atherosclerotic lesion, the vessel interferes with the development of atherothrombosis regardless of the localization of the vascular process (cerebrovascular, cardiovascular or peripheral lesions).
Indications
- prevention of atherothrombotic complications in adult patients with myocardial infarction (with a duration of several days to 35 days), ischemic stroke (with a duration of 7 days to 6 months) or occlusive disease of peripheral arteries;
- prophylaxis of atherothrombotic complications in adult patients with acute coronary syndrome with ST segment elevation with the possibility of performing thrombolytic therapy (in combination with acetylsalicylic acid);
- prevention of atherothrombotic complications in adult patients with acute coronary syndrome without ST segment elevation (unstable angina, myocardial infarction without Q wave), incl. in patients undergoing stenting (in combination with acetylsalicylic acid);
- prevention of atherothrombotic and thromboembolic complications, including stroke, in atrial fibrillation in adult patients with at least one risk factor for vascular complications that can not take indirect anticoagulants and have a low risk of bleeding (in combination with acetylsalicylic acid).


.